P2RY12

(redirected from P2Y)

P2RY12

A gene on chromosome 3q24-q25 that encodes a G protein-coupled receptor for various drugs as well adenosine and uridine nucleotides.
Mentioned in ?
References in periodicals archive ?
The ATP released through Panx1 channels contributes, in great part, to the a1-adrenoceptor-mediated vasoconstriction through the activation of P2Y receptors.
2001) Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors.
Alem da influencia vascular, a vasodilatacao tambem tem uma interferencia neural, mediada pela acao do ATP, atraves dos receptores purinergicos P2Y e P2X.
1), which are broadly expressed on immune and other cells, are members of the P2 class of receptors for extracellular nucleotides and are classified into two families, P2Y and P2X (Burnstock and Boeynaems, 2014).
In the setting of percutaneous coronary intervention with a bare metal or drug-eluting stent for patients with either non-ST-elevation ACS or ST-elevation MI, the AHA/ACC guidelines give a class I recommendation for at least 12 months of dual-antiplatelet therapy (DAPT) with aspirin and a P2Y inhibitor.
He HY, Zheng J, Li Y, Heng WJ, Fang WG (2005) SHP2 and MKP5 in P2Y purinergic receptor-mediated prostate cancer invasion.
Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone inhibits expression of P2Y receptors in cystic fibrosis tracheal gland cells.
11 Although insulin suppresses P2Y mediated platelet aggregation in healthy subjects12 it is known that if there is insulin resistance such as DM accompanying central obesity obesity and HT there is unresponsiveness to the antiaggregant effect of insulin.
Substances known to specifically block the platelet's P2Y 12 receptor include the thienopyridine class of drugs, including clopidogrel, prasugrel, ticagrelor, and ticlopidine.
Effects of Elevated Fibrinogen, Factor VIII, and von Willebrand factor on the INNOVANCE[R] PFA P2Y cartridge
Key classes of mechanism of action include endothelin receptor antagonists, platelet aggregation inhibitors, phosphodiesterase inhibitors, serotonin pathway antagonists, angiotensin receptor antagonists, P2Y 12 receptor inhibitors, PDE5 inhibitors, prostacyclin (PGI2) agonists, nitric oxide synthetase inhibitors.